CN104619321A - 用于增加cftr活性的方法 - Google Patents

用于增加cftr活性的方法 Download PDF

Info

Publication number
CN104619321A
CN104619321A CN201380023856.4A CN201380023856A CN104619321A CN 104619321 A CN104619321 A CN 104619321A CN 201380023856 A CN201380023856 A CN 201380023856A CN 104619321 A CN104619321 A CN 104619321A
Authority
CN
China
Prior art keywords
cftr
methods
experimenter
mucociliary clearance
depth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380023856.4A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·M·罗
马克·德雷恩斯菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of CN104619321A publication Critical patent/CN104619321A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380023856.4A 2012-04-06 2013-03-15 用于增加cftr活性的方法 Pending CN104619321A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Publications (1)

Publication Number Publication Date
CN104619321A true CN104619321A (zh) 2015-05-13

Family

ID=49301152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380023856.4A Pending CN104619321A (zh) 2012-04-06 2013-03-15 用于增加cftr活性的方法

Country Status (8)

Country Link
US (2) US20150065539A1 (https=)
EP (1) EP2833885A4 (https=)
JP (1) JP6525203B2 (https=)
CN (1) CN104619321A (https=)
AU (2) AU2013243857A1 (https=)
CA (1) CA2869257A1 (https=)
HK (1) HK1206995A1 (https=)
WO (1) WO2013151758A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20050176761A1 (en) * 2003-12-23 2005-08-11 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
WO2011030163A1 (en) * 2009-09-12 2011-03-17 Reckitt Benckiser Llc Use of guaifenesin for inhibiting mucin secretion
WO2011115778A2 (en) * 2010-03-15 2011-09-22 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
CN102231990A (zh) * 2008-08-13 2011-11-02 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP3037415A1 (en) * 2010-03-19 2016-06-29 Vertex Pharmaceuticals Inc. Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS56096B1 (sr) * 2011-05-18 2017-10-31 Concert Pharmaceuticals Inc Deuterisani derivati ivakaftora

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20050176761A1 (en) * 2003-12-23 2005-08-11 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
CN102231990A (zh) * 2008-08-13 2011-11-02 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
WO2011030163A1 (en) * 2009-09-12 2011-03-17 Reckitt Benckiser Llc Use of guaifenesin for inhibiting mucin secretion
WO2011115778A2 (en) * 2010-03-15 2011-09-22 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATHAN S. ALEXANDER, M.D. ET AL.: "Resveratrol Has Salutary Effects on Mucociliary Transport and Inflammation in Sinonasal Epithelium", 《THE LARYNGOSCOPE》, vol. 121, no. 6, 30 June 2011 (2011-06-30), pages 1313 - 1319, XP002748788, DOI: 10.1002/lary.21798 *
牟小芬等: "囊性纤维化发病机制的研究进展", 《国外医学呼吸系统分册》, vol. 22, no. 2, 31 December 2002 (2002-12-31), pages 85 - 87 *

Also Published As

Publication number Publication date
HK1206995A1 (en) 2016-01-22
US10300052B2 (en) 2019-05-28
EP2833885A4 (en) 2015-12-16
JP6525203B2 (ja) 2019-06-05
AU2018200192B9 (en) 2019-07-25
AU2013243857A1 (en) 2014-10-16
CA2869257A1 (en) 2013-10-10
WO2013151758A2 (en) 2013-10-10
JP2015521157A (ja) 2015-07-27
EP2833885A2 (en) 2015-02-11
US20170266177A1 (en) 2017-09-21
US20150065539A1 (en) 2015-03-05
AU2018200192B2 (en) 2019-06-06
AU2018200192A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
Brand et al. Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis
Chambers et al. Liquid movement across the surface epithelium of large airways
US7524820B1 (en) Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology
EP3045912B1 (en) A rapid quantitative assay to measure cftr function in a primary intestinal culture model
EP3925959A1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
CN104367988A (zh) 卡贝缩宫素鼻用制剂和治疗孤独症的方法
KR20170141757A (ko) 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
CN101583377A (zh) 纤维化的治疗
US10413583B2 (en) Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
KR20240024104A (ko) 형광 프로브
Shoyele et al. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation
AU2018200192B9 (en) Methods for increasing CFTR activity
Schultz et al. Pulmonary insulin-like growth factor I delivery from trehalose and silk-fibroin microparticles
Jaehde et al. Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells
CA2584195A1 (fr) Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20190000865A1 (en) Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
CN114829378A (zh) 基于肽的合成氯离子转运蛋白
US9018173B2 (en) Materials and methods for suppressing inflammatory and neuropathic pain
Yamamoto et al. Control of pulmonary absorption of water-soluble compounds by various viscous vehicles
CN110742891A (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
US20190040073A1 (en) Nonanoic and decanoic acid derivatives and uses thereof
Zhang et al. Effects of ephedrine on human nasal ciliary beat frequency
US20150202212A1 (en) Methods for identifying agents for treating smooth muscle disorders and compositions thereof
Nagelkerke et al. Quantification and Visualization of the Transport of Octreotide
Alqahtani Development and application of in vitro approaches to assess the interactions of aerosolised drugs with pulmonary mucus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150513